Long-Term Extension Study of Pitavastatin in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia

January 25, 2010 updated by: Kowa Research Europe

Open-Label, Long-Term (1 Year) Extension Study of Pitavastatin in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia

This study is a long-term follow-up protocol for patients who participated in study NK-104-3.01EU or study NK-104-3.02EU.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Patients from the NK-104-3.01EU and NK-104-3.02EU studies will continue to receive either pitavastatin or the comparator statin for 1 year.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
1355

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Denmark
      • Copenhagen, Denmark
        • Copenhagen University Hospital
      • Copenhagen, Denmark
        • Medical Center
      • Copenhagen Nv, Denmark
        • Y Forskning, Bispebjerg Hospital
      • Frederiksberg, Denmark
        • Frederiks Hospital, Kardiologisk
      • Hellerup, Denmark
        • Kolesterollaboratoriet
      • Vejle, Denmark
        • CCBR A/S
  • Finland
      • Helsinki, Finland
        • GERI-MED Oy
      • Helsinki, Finland
        • Kaisaniemen Laakariasema
      • Helsinki, Finland
        • Keravan Laakarikeskus
      • Tampere, Finland
        • SOK-Tyoterveyshuolto
      • Turku, Finland
        • TYKS University Hospital
  • Germany
      • Bad Soden/Taunus, Germany
        • Kardiologische Gemeinschaftspraxis Prof. Reifart
      • Beckum, Germany
        • Praxis Dr. Boenninghoff
      • Berlin, Germany
        • Klinische Forschung Berlin Mitte
      • Berlin-Spandau, Germany
        • Gemeinschaftspraxis am Bahnhof
      • Chemnitz, Germany
        • Pharmakologisches Studienzentum Chemnitz
      • Dresden, Germany
        • GWT-TUK mbH, Zentrum fur Klinische Studien
      • Frankfurt Am Main, Germany
        • Internistische Diabetische Schwerpunktpraxis Dr.
      • Goch, Germany
        • Gemeinschaftspraxis Dr. Krause, Th. Menke
      • Hamburg, Germany
        • Klinische Forschung Hamburg
      • Heidelberg, Germany
        • Innere Medizin I/Medizinische Klinik
      • Lampertheim, Germany
        • Gemeinschaftspraxis H. Holz Dr. Med, K. W. Klingl
      • Leipzig, Germany
        • ZET-Studien GmbH Leipzig
      • Mainz, Germany
        • Internistische Gemeinschaftspraxis
      • Mannheim, Germany
        • Praxis Dr. Wachter
      • Melcherstaette, Germany
        • Gemeinschaftspraxis Melcherstaette
      • Messkirch, Germany
        • Gemeinschaftspraxis Dr. Senftleber, Dr. Kohler
      • Offenbach/M, Germany
        • Praxisgemeinschaft im Kleinen Biergrund
      • Weinheim, Germany
        • Gemeinschaftspraxis Drs. Mockesch
      • Wiesbaden, Germany
        • Intermed Institud fur Klinische Forschung und Arzn
      • Worpswede, Germany
        • Gemeinschaftspraxis Dr. Emden, Frank Drewes
  • India
      • Andhra Pradesh, India, 500034
        • Care Hospital
      • Andhra Pradesh, India, 500082
        • School of Diabetology, Nizam Institute of Medical Sciences
      • Bangalore, India
        • Bhagwan Mahaveer Jain Heart Centre
      • Chennai, India
        • Sri Ramachandra Medical College Hospital
      • Gujarat, India, 380054
        • Heart Care Clinic
      • Hyderabad, India
        • Apollo Hospitals
      • Hyderabad, India
        • CARE Group of Hospitals
      • Karnataka, India, 560034
        • St. John's Medical College Hospital
      • Maharashtra, India, 400007
        • Bathia Hospital
      • Maharashtra, India, 400022
        • LTMMC & General Hospital
      • Maharashtra, India, 400027
        • Sir J. J. Group of Hospitals
      • Maharashtra, India, 411001
        • King Edward Medical College & Hospital
      • Maharashtra, India, 411001
        • Ruby Hall Clinic
      • Maharashtra, India, 411033
        • Lokmanya Hospital
      • Mumbai, India
        • PD Hinduja Hospital
      • New Delhi, India, 110060
        • Sir Gagaram Hospital
      • Tamil Nadu, India, 600006
        • Apollo Hospital
      • Tamil Nadu, India, 641004
        • Department of Cardiology
  • Israel
      • Beersheva, Israel
        • Department of Internal Medicine, Soroka Medical Center
      • Haifa, Israel
        • Department of Internal Medicine A, Rambal Medical Center
      • Holon, Israel
        • Department of Internal Medicine, Wolfson Medical Center
      • Jerusalem Ein Kerem, Israel
        • Center for Research, Hadassah University Hospital
      • Kfar Saba, Israel
        • Meir Hospital
      • Mount Scopus Jerusalem, Israel
        • Department of Medicine, Hadassah Medical Center
      • Safed, Israel
        • Department of Internal Medicine, Rivka Sieff Medical Center
      • Tel Aviv, Israel
        • Institute of Metabolic Diseases
      • Tel Hashomer, Israel
        • Institute of Lipid & Atherosclerosis Research
  • Italy
      • Bologna, Italy
        • Dipartimento di Medicina Clinica e Biotecnologia Applicata
      • Chieti, Italy
        • Centro di Ricerca Clinica
      • Ferrara, Italy
        • Gerontologia e Geriatria - Universita degli Studi
      • Genova, Italy
        • Dipartimento di Medicina Interna DIMI
      • Modena, Italy
        • Universita di Modena e Reggio Emilia, Policlinico
      • Napoli, Italy
        • Dipartimento di Medicina Clinica e Sperimentale
      • Palermo, Italy
        • Medicina Clinica e delle Patologie Emergenti
      • Parma, Italy
        • Dipartimento di Medicina Interna e Scienze Biomediche
      • Treviglio, Italy
        • U.O. Malattie Metaboliche e Diabetologia
      • Trieste, Italy
        • Azienda Ospedaliero-Universitaria
  • Netherlands
      • Breda, Netherlands
        • Andromed Breda
      • Breda, Netherlands
        • Middellaan 5
      • Eindhoven, Netherlands
        • Andromed Eindhoven
      • Eindhoven, Netherlands
        • Bomanshof 8
      • Groningen, Netherlands
        • Andromed Noord
      • Groningen, Netherlands
        • Damsterdiep 9
      • Hoorn, Netherlands
        • Vasculair Onderzoek Centrum Hoorn
      • Leiden, Netherlands
        • Andromed Leiden
      • Leiden, Netherlands
        • Doezastraat 1
      • Nijmegen, Netherlands
        • Andromed Nijmegen
      • Nijmegen, Netherlands
        • Kamerlingh Onnesstraat 16-18
      • Rotterdam, Netherlands
        • Andromed Rotterdam
      • Rotterdam, Netherlands
        • Mathenesserlaan 247
      • Sliedrecht, Netherlands
        • Albert Schweitzer Ziekenhuis
      • Velp, Netherlands
        • Andromed Oost
      • Velp, Netherlands
        • Reigerstraat 30
      • Wp Tiel, Netherlands
        • Rivierenland Tiel
      • Zoetermeer, Netherlands
        • Andromed Zoetermeer
      • Zoetermeer, Netherlands
        • Parkdreef 142
  • Norway
      • Kongsberg, Norway
        • Nyomen Legekontor
      • Oslo, Norway
        • Radhuset Spesialistsenter
      • Oslo, Norway
        • Rikshospitalet - University Hospital
      • Skedsmokorset, Norway
        • Skedsmo Medisinske Senter A.S.
  • Poland
      • Bialystok, Poland
        • Podlaski Ośrodek Kardiologii
      • Gruziadz, Poland
        • NZOZ GCP Dobra Praktyka Lekaska
      • Katowice, Poland
        • NZOZ Terapia Optima
      • Losice, Poland
        • NZOZ Esculap, Przychodnia Lekary Rodzinnych
      • Siedlce, Poland
        • NZOZ Centrum, Poradnia Kardiologiczna
      • Tarnow, Poland
        • Spec. Gab. Lek. Internistyczno-Kardiologicznly
      • Tychy, Poland
        • Woj.Szp.Spec.Nr 1 im. Prof. J. Gasinskiego
      • Warszawa, Poland
        • Instytut Zywnosci i Zywienia
      • Warszawa, Poland
        • Lecznica PROSEN SMO
      • Warszawa, Poland
        • Szpital Wolski,im. Dr A. Gostynskiej
  • Russian Federation
      • Kemerovo, Russian Federation
        • Kemerovo Cardiology Dispensary
      • Moscow, Russian Federation
        • Central Clinical Hospital 1 of RZD
      • Moscow, Russian Federation
        • City Clinical Hospital 23
      • Moscow, Russian Federation
        • City Clinical Hospital 64
      • Moscow, Russian Federation
        • Federal State Institution Out-Patient Clinic 3 of Russian Federation of President’s Management
      • Moscow, Russian Federation
        • Moscow City Clinical Hospital 68
      • Moscow, Russian Federation
        • Moscow Regional Research Clinic Institute n.a.M.F.Vladimirov, Department of Therapy
      • Moscow, Russian Federation
        • State Educational Institution of Higher Professional Education “Moscow State University of Medicine and Dentistry of Federal Agency of Health Care and Social Developmentâ€�, Department of Internal Diseases and Rheumatology based at City Clinica
      • Moscow, Russian Federation
        • State Educational Institution of Higher Professional Education “Moscow State University of Medicine and Dentistry of Federal Agency of Health Care and Social Developmentâ€�, Hospital Therapy Department # 1 based at City Clinical Hospital # 40
      • Moscow, Russian Federation
        • State Educational Institution of Higher Professional Education “Moscow State University of Medicine and Dentistry of Federal Agency of Health Care and Social Developmentâ€�, Hospital Therapy Department #1 based at City Clinical Hospital # 52
      • Moscow, Russian Federation
        • State Educational Institution of Higher Professional Education “Russian State Medical University Federal Agency of Health Care and Social Developmentâ€�, Department of Polyclinic Therapy based at Diagnostic Center # 1
      • Moscow, Russian Federation
        • State Educational Institution of Higher Professional Education “Russian State Medical University Federal Agency of Health Care and Social Developmentâ€�, Department of Therapy based at City Hospital # 4
      • Moscow, Russian Federation
        • State Institution “Research Institute of Physical and Chemical Medicineâ€� of Federal Agency of Health Care and Social Development, Laboratory of Clinical Cardiology based at Bauman City Hospital # 29
      • Moscow, Russian Federation
        • State Institution “Russian Cardiology Research Complexâ€� of Federal Agency of Health Care and Social Development, Myasnikov Clinical Cardiology Institute, Department of Hemodialysis and Plasmapheresis
      • Moscow, Russian Federation
        • State Research Center for Preventive Medicine
      • Moscow, Russian Federation
        • State Educational Institution of Higher Professional Education “Russian State Medical University of Federal Agency of Health Care and Social Developmentâ€�, Department of Hospital Therapy #1 based at City Clinical Hospital #15, Cardiology Depar
      • Novosibirsk, Russian Federation
        • Novosibirsk Reg. Clinical Cardiology Dispensary
      • Saint Petersburg, Russian Federation
        • Central Medical Unit 122, St. Pb
      • Saint Petersburg, Russian Federation
        • Clinical Hospital of Russian Academy of Sciences
      • Saint Petersburg, Russian Federation
        • Consulting and Diagnostic Center 85
      • Saint Petersburg, Russian Federation
        • Krestovsky Island Medical Institute
      • Saint Petersburg, Russian Federation
        • Pokrovskaya City Hospital
      • Saint Petersburg, Russian Federation
        • St. Petersburg State Medical Institution “Out-patient Clinic # 109â€�
      • Saint Petersburg, Russian Federation
        • State Educational Institution of Higher Professional Education, “Saint-Petersburg State Medical University n.a.Academician I.P.Pavlov of Federal Agency of Health Care and Social Developmentâ€�, Chair and Department of Faculty Therapy
      • Saint Petersburg, Russian Federation
        • State Educational Institution of Higher Professional Education, “Saint-Petersburg State Medical University n.a.Academician I.P.Pavlov of Federal Agency of Health Care and Social Developmentâ€�, Institute of Cardiovascular Diseases
      • Saint Petersburg, Russian Federation
        • St.Petersburg State Medical Institution “Pokrovskaya City Hospitalâ€�, Cardiology Department #2
  • Spain
      • Alicante, Spain, 03690
        • Hospital de San Vicente
      • Barcelona, Spain
        • Hospital Universitario de Bellvitge
      • Barcelona, Spain, 08025
        • Hospital Santa Creu i Sant Pau
      • Barcelona, Spain
        • Hospital Vall d'Hebron
      • Cordoba, Spain
        • Hospital Universitario Reina Sofia
      • Madrid, Spain
        • Fundacion Jimenez Diaz
      • Madrid, Spain
        • Hospital Clinico San Carlos
      • Madrid, Spain, 28000
        • Hospital Ramón y Cajal
      • Madrid, Spain, 28037
        • Centro de Especialidades Pedro Gonzalez Bueno
      • Oviedo, Spain, 33010
        • Centro de Salud de Ventanielles
      • Santander, Spain, 3908
        • Hospital Marqués de Valdecilla
      • Santiago de Compostela, Spain
        • Hospital Clínico Universitario de Santiago
      • Sevilla, Spain, 41013
        • Hospital Virgen del Roci-o
      • Valencia, Spain
        • Hospital de Sagunto
      • Valencia, Spain, 46017
        • Hospital Dr. Peset
      • Zaragoza, Spain, 50009
        • Hospital Clinico Lozano Blesa
      • Zaragoza, Spain, 50009
        • Hospital Miguel Servet
    • Alicante
      • San Juan, Alicante, Spain
        • Hospital Clinico S. Juan de Alicante
    • Barcelona
      • Villaroel, Barcelona, Spain
        • Hospital Clinic i Provincial
  • Sweden
      • Angelhom, Sweden
        • Angelholms Sjukhus, Medicinkliniken
      • Gothenburg, Sweden
        • Sahlgrenska University Hospital, Intermedicin
      • Helsingborg, Sweden
        • Hjärtmottagningen
      • Karineholm, Sweden
        • Lakarcentrum Nyponet
      • Ludvika, Sweden
        • Medicinkliniken
      • Sandviken, Sweden
        • Huslakaren i Sandviken
      • Sandviken, Sweden
        • Narsjukhuset Sandviken, Kardiologlab, Medicin
      • Sodertalje, Sweden
        • Hjart & Karlcenter
      • Stockholm, Sweden
        • Karolinska Universitetssjukhuset
      • Varberg, Sweden
        • Hjarthuset AB
  • United Kingdom
      • Bath, United Kingdom
        • Oldfield Surgery
      • Bath, United Kingdom
        • St James's Surgery
      • Bath, United Kingdom
        • St Michael's Partnership
      • Bath, United Kingdom
        • The Pulteney Practice
      • Birmingham, United Kingdom
        • Birmingham Clinical Research Centre
      • Bolton, United Kingdom
        • Stonehill Medical Center
      • Chesterfield, United Kingdom
        • Avondale Surgery
      • Chorley, United Kingdom
        • Chorley Clinical Research Centre
      • Cornwall, United Kingdom
        • Saltash Health Center
      • Dronfield, United Kingdom
        • Gomersal Lane Surgery
      • Irvine, United Kingdom
        • Townhead Research
      • Liverpool, United Kingdom
        • Crosby Clinical Research Centre
      • Maidenhead, United Kingdom
        • The Symons Medical Center
      • Manchester, United Kingdom
        • Manchester Clinical Research Centre
      • Nottingham, United Kingdom
        • Greenwood Medical Center
      • Plymouth, United Kingdom
        • Knowle House Surgery
      • Reading, United Kingdom
        • Reading Clinical Research Centre
      • Sheffield, United Kingdom
        • Elm Lane Surgery
      • Sheffield, United Kingdom
        • The Burngreave Surgery
      • Southampton, United Kingdom
        • Brook Lane Surgery
      • Surrey, United Kingdom
        • St Helier Hospital
      • Wiltshire, United Kingdom
        • Box Surgery
      • Wiltshire, United Kingdom
        • Bradford Road Medical Center
      • Wiltshire, United Kingdom
        • Eastleigh Surgery
      • Wiltshire, United Kingdom
        • Lovemead Group Practice
      • Wiltshire, United Kingdom
        • Rowden Medical Partnership
      • Wiltshire, United Kingdom
        • St Chad's Surgery
      • Wiltshire, United Kingdom
        • The Health Centre
      • Wiltshire, United Kingdom
        • The Porch Surgery
      • Yorkshire, United Kingdom
        • The Burns Medical Practice

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients have completed 12 weeks of treatment in Study NK-104-301 (NCT00249249) or NK-104-302 (NCT00309777)
  • Patients who have not developed any treatment emergent and, in the opinion of the investigator, related adverse event (AE) of clinical significance where the investigator is uncomfortable with continuing the patient on therapy with pitavastatin.
  • Patients who have been following a fat and cholesterol restrictive diet.

Exclusion Criteria:

  • Any conditions which may cause secondary dyslipidemia should be reassessed at the beginning of the follow-up study.
  • Uncontrolled diabetes mellitus should be reassessed at the beginning of the follow-up study.
  • Abnormal pancreatic, liver, or renal function
  • Abnormal serum ALAT/SGPT/ALT, ASAT/SGOT/AST, or creatine kinase (CK) above the pre-specified level
  • Significant heart disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Pitavastatin 4 mg QD
Pitavastatin 4 mg once daily
Drug: Pitavastatin
Pitavastatin 4 mg once daily

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)
Time Frame: Baseline to 52 Weeks
Mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C)
Baseline to 52 Weeks

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Change From Baseline in Total Cholesterol
Time Frame: Baseline to 52 weeks
Mean percent change from baseline in total cholesterol
Baseline to 52 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Kowa Research Europe

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Dragos Budinski, Med Dr., Medical Director

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
July 1, 2006

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
November 1, 2007

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
November 1, 2007

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
February 10, 2006

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 11, 2006

First Posted (Estimate)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
May 15, 2006

Study Record Updates

Last Update Posted (Estimate)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
February 2, 2010

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 25, 2010

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
January 1, 2010

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • NK-104-307
  • 2005-001112-41

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings